White Papers
May 9, 2025

Cell & Gene Scale-Up: How Supply Chain Design Evolves as a Company Matures

By Peter Martens and Marleen Overbeeke

When cell and gene therapies transition from the clinical stage to the commercial, their supply chains must evolve to handle greater volume and complexity. However, the change doesn’t end there. Ongoing evolution and optimization are needed as the company matures. In this paper, we explore the nature of those continuing changes and the implications for cell and gene therapy companies as they progress through different phases of maturity.

Free Download

White Papers
January 6, 2025

How to Find the Right European Distribution Partner & Build a Successful Long-Term Relationship

By Sander Smit, Corné van Raak, and Ronald van Zitteren

This paper provides guidance to biopharma companies who are working to build a successful, long-term partnership with a third party logistics provider (3PL) in Europe. It addresses three basic questions:

How can a biopharma company select the right 3PL partner?
What attributes make one potential partner better than another?
Once a partnership is established, what factors help drive a positive, value-added relationship for the long term?

Free Download

White Papers
July 2, 2024

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up and operationalizing a supply chain in Europe for a new biopharma therapy. Specifically, it outlines the key cost drivers, along with the various “levers” that decision makers can use to affect those costs.

Free Download

White Papers
March 22, 2024

Adding (Ultra-) Rare Disease Products to Your Company’s Portfolio: It’s a Whole New “Ball Game”

Interest in rare disease (RD) therapies continues to rise, with many established companies incorporating RD therapies into their portfolios for the first time. This paper:

Describes the special challenges associated with distributing RD products
Outlines the key steps and deliverables for developing and implementing supply chains for RD therapies
Summarizes the pitfalls that biopharma companies must avoid when working to establish reliable supply chains in rare diseases.

Free Download

White Papers
September 27, 2023

Ensuring a Reliable Biopharmaceutical Supply in the EU

A combination of economic and regulatory factors are driving up the cost and complexity of biopharma supply chains in the EU. This paper explores those factors and outlines both “upstream” and “downstream” strategies that pharma and biotech companies can use to better manage cost, complexity, and risk.

Free Download

White Papers
October 27, 2022

Webinar Summary – Supply Chains for Cell and Gene Therapies

Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common. However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.

On October 20, 2022, AIM conducted a webinar on how companies can orchestrate successful supply chains for ATMPs. This paper provides a written summary of the webinar discussion.

For a time, webinar registrants can also access a recorded copy of the webinar here.

Free Download

White Papers
October 30, 2021

Webinar Summary – Launching a First Product in Europe: The Supply Chain Perspective

On 27 October 2021, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.

Our panel of experts included:

Pim Van Der Aar, Co-Founder & Managing Director, AIM (Moderator)
Christian Ellereit, Head of Finance, Europe, Travere Therapeutics
Ronald van Zitteren, Principal, AIM
Joop Wijdeven, Associate, AIM

The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.